WO2010109168A3 - Angiogenesis methods, medicaments and agents - Google Patents

Angiogenesis methods, medicaments and agents Download PDF

Info

Publication number
WO2010109168A3
WO2010109168A3 PCT/GB2010/000516 GB2010000516W WO2010109168A3 WO 2010109168 A3 WO2010109168 A3 WO 2010109168A3 GB 2010000516 W GB2010000516 W GB 2010000516W WO 2010109168 A3 WO2010109168 A3 WO 2010109168A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenesis
medicaments
agents
tei
test agent
Prior art date
Application number
PCT/GB2010/000516
Other languages
French (fr)
Other versions
WO2010109168A2 (en
Inventor
David Alan Baker
Mark Guido Roukens
Original Assignee
Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc) filed Critical Academisch Ziekenhuis Leiden Also Acting Under The Name "Leiden University Medical Center" (Lumc)
Publication of WO2010109168A2 publication Critical patent/WO2010109168A2/en
Publication of WO2010109168A3 publication Critical patent/WO2010109168A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Abstract

A method of modulating angiogenesis in an individual in need thereof comprising administering an agent that modulates at least one function or activity of TeI to the individual. A method of identifying a modulator of angiogenesis comprising: a) providing TeI or a portion or a variant thereof, said portion or variant being capable of binding to at least one of DNA and CtBP; b) providing a test agent; c) assessing whether the test agent modulates at least one function or activity of TeI; and d) assessing whether the test agent modulates angiogenesis in an assay for angiogenesis.
PCT/GB2010/000516 2009-03-23 2010-03-23 Angiogenesis methods, medicaments and agents WO2010109168A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0904904.0 2009-03-23
GBGB0904904.0A GB0904904D0 (en) 2009-03-23 2009-03-23 Angiogenesis methods, medicaments and agents

Publications (2)

Publication Number Publication Date
WO2010109168A2 WO2010109168A2 (en) 2010-09-30
WO2010109168A3 true WO2010109168A3 (en) 2015-08-27

Family

ID=40639952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/000516 WO2010109168A2 (en) 2009-03-23 2010-03-23 Angiogenesis methods, medicaments and agents

Country Status (2)

Country Link
GB (1) GB0904904D0 (en)
WO (1) WO2010109168A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503222A (en) 2011-01-18 2014-02-13 エバリスト ジェノミックス， インコーポレイテッド Prognostic signs of colorectal cancer recurrence
CN108085336A (en) * 2016-11-21 2018-05-29 中国科学院上海生命科学研究院 EGFP expression vector establishments based on col2a1 promoters and the application in transgenic zebrafish

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147528A1 (en) * 2007-05-24 2008-12-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
EP0763202A4 (en) 1994-05-23 1998-12-09 Smithkline Beecham Corp Encoded combinatorial libraries
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147528A1 (en) * 2007-05-24 2008-12-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BOILY GINO ET AL: "Identification of transcripts modulated by ETV6 expression", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB LNKD- DOI:10.1111/J.1365-2141.2006.06377.X, vol. 136, no. 1, 1 January 2007 (2007-01-01), pages 48 - 62, XP009138207, ISSN: 0007-1048, [retrieved on 20061027] *
EDEL MICHAEL J: "The ETS-related factor TEL is regulated by angiogenic growth factor VEGF in HUVE-cells", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 18, no. 6A, 1 November 1998 (1998-11-01), pages 4505 - 4509, XP009138186, ISSN: 0250-7005 *
KIM M S ET AL: "Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/86507, vol. 7, no. 4, 1 April 2001 (2001-04-01), pages 437 - 443, XP002278083, ISSN: 1078-8956 *
ONNEBO S M N ET AL: "TEL/ETV6 is important for angiogenesis, gut development and neuronal cell survival", BIOCHEMICAL SOCIETY TRANSACTIONS, PORTLAND PRESS LTD, GB, vol. 32, no. Part 4, 1 August 2004 (2004-08-01), pages 94A, XP009138225, ISSN: 0300-5127 *
VAN ROMPAEY L ET AL: "TEL induces aggregation in transformed cells and induces tube formation in NIH3T3-UCLA cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1006/BBRC.2002.6513, vol. 291, no. 4, 8 March 2002 (2002-03-08), pages 820 - 828, XP009138206, ISSN: 0006-291X, [retrieved on 20020305] *
WANG LI CHUN ET AL: "Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 16, no. 14, 1 January 1997 (1997-01-01), pages 4374 - 4383, XP009138183, ISSN: 0261-4189 *
WANG LILIN ET AL: "TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3", ONCOGENE, vol. 20, no. 28, 21 June 2001 (2001-06-21), pages 3716 - 3725, XP009138403, ISSN: 0950-9232 *
WILLIAMS R J: "TRICHOSTATIN A, AN INHIBITOR OF HISTONE DEACETYLASE, INHIBITS HYPOXIA-INDUCED ANGIOGENESIS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB LNKD- DOI:10.1517/13543784.10.8.1571, vol. 10, no. 8, 1 August 2001 (2001-08-01), pages 1571 - 1573, XP009029994, ISSN: 1354-3784 *

Also Published As

Publication number Publication date
GB0904904D0 (en) 2009-05-06
WO2010109168A2 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
WO2014099979A3 (en) Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
NO20052668L (en) Immediate release dosage form having capsule with apertures therein
WO2007076132A3 (en) Compositions comprising oriented, immobilized macromolecules and methods for their preparation
WO2008115518A3 (en) Biomarkers of sirtuin activity and methods of use thereof
EP1828768A4 (en) Systems and methods for identifying diagnostic indicators
DE602006021533D1 (en) Whey protein carrier for the release of active substances
EP1875098A4 (en) Brake pad with identification means and system and method for the identification of brake pads
DE112009001876T8 (en) Driving diagnosis information providing device and system
EP2050398A4 (en) Pressing device, and ultrasonic probe and ultrasonic diagnosis device using the pressing device
DE102005023067A8 (en) Device for testing the sealing load capacity
DK1831240T3 (en) 18-methyl-19-nor-17pregn-4-ene-21,17-carbolactones and pharmaceutical preparations containing these
EG25122A (en) Method and device for metering medicaments.
MY147374A (en) Aptamer against midkine and use thereof
EP2004863A4 (en) Reaction, performance and response time testing system
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP2128273A4 (en) Primer set for gene amplification, gene amplification reagent containing the same and use thereof
EP2754668A3 (en) Biological materials and uses thereof
WO2006108156A3 (en) Dispensing apparatus for diagnostic test strip and/or medicine
EP1990634A4 (en) Biosensor chip, biosensor system, and measuring device thereof
FR2892646B1 (en) HETEROGENEUS CATALYTIC SYSTEM AND USE THEREOF
BRPI0822889A2 (en) Backstop device, and method for testing the operational integrity of a backstop device.
WO2010109168A3 (en) Angiogenesis methods, medicaments and agents
WO2008022035A3 (en) Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
WO2010000874A3 (en) Marker sequences for inflammatory prostate diseases, prostate carcinoma and their use
WO2007041397A3 (en) Targeted pharmaceuticals and ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10723729

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10723729

Country of ref document: EP

Kind code of ref document: A2